Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 20/20 | 0.44 |
| ▸ | CBL | P22681 | 16/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25413551 | 1.00 | CBLB (0.44) | CBLBCBL | |
| SCHEMBL25413018 | 0.86 | CBLB (0.48) | CBLBCBL | |
| SCHEMBL25413016 | 0.86 | CBLB (0.48) | CBLBCBL | |
| SCHEMBL25412706 | 0.86 | CBLB (0.41) | CBLBCBL | |
| SCHEMBL25412703 | 0.86 | CBLB (0.41) | CBLBCBL | |
| SCHEMBL25413303 | 0.83 | CBLB (0.38) | CBLBCBL | |
| SCHEMBL30598910 | 0.83 | CBLB (0.38) | CBLBCBL | |
| SCHEMBL25180189 | 0.82 | CBLB (0.32) | CBLB | |
| SCHEMBL31275178 | 0.82 | CBLB (0.42) | CBLBCBL | |
| SCHEMBL30184959 | 0.82 | CBLB (0.52) | CBLBCBL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2025-10-02 | — | — | US | disclosed |
| WO-2025067468-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2025-04-03 | — | — | WO | disclosed |
| EP-4490152-A1 | ACTIVATORS OF EFFECTOR T CELLS | Orum Therapeutics Inc. (KR) | 2025-01-15 | — | — | EP | disclosed |
| WO-2024255762-A1 | CBL-B INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2024-12-19 | — | — | WO | disclosed |
| WO-2023170608-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2023-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | CBLB, CBL, CBLC | CBLB 1/4885CBL 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.